echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Oncologist: Clinical outcome, treatment toxicity and healthcare utilization of elderly aggressive non-Hodgkin's lymphoma (NHL)

    Oncologist: Clinical outcome, treatment toxicity and healthcare utilization of elderly aggressive non-Hodgkin's lymphoma (NHL)

    • Last Update: 2021-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although balancing the effects of treatment and the risk of complications is essential for elderly patients with aggressive non-Hodgkin's lymphoma (NHL), few studies have described the clinical outcomes, toxicity rates, and utilization of healthcare in these patients
    .


    Therefore, a research team from the United States conducted a retrospective study to evaluate the clinical characteristics, prognosis, treatment toxicity, unplanned hospitalization rate, and ICU hospitalization in patients with aggressive non-Hodgkin lymphoma (NHL) aged 65 years or older.


    Although balancing the effects of treatment and the risk of complications is essential for elderly patients with aggressive non-Hodgkin's lymphoma (NHL), few studies have described the clinical outcomes, toxicity rates, and utilization of healthcare in these patients


    The study included 295 patients with a median age of 73 years (range 65-100 years); 96/295 or 32.
    5% of patients were between 65 and 69 years old; 77/295 or 26.
    1% of patients were 70- 74 years old; 59/295 (20.
    0%) patients were 75-79 years old; 63/295 (21.
    4%) patients were over 80 years old
    .


    Most patients received CHOP treatment (194/295, 65.


    The study included 295 patients with a median age of 73 years (range 65-100 years); 96/295 or 32.


    Treatment and prognosis

    Treatment and prognosis

    The ORR of the total population was 86.
    9% (253/291), and the complete remission (CR) rate was 84.
    2% (245/291)
    .


    The median follow-up time was 5.


    The ORR of the total population was 86.


    After treatment, the incidence of grade 3-5 non-hematological toxicity was 42.


                        3-5 levels of toxicity related factors

      3-5 levels of toxicity related factors

    Among patients aged 65-69, 70-74, 75-79, and 80 years old, the 5-year OS rate was 82.
    2% (95%CI, 72.
    4 -88.
    7) and 72.
    0% (95%CI, 59.
    7 -81.
    1), 73.
    6% (95% CI, 59.
    2-83.
    6) and 66.
    4% (95% CI, 52.
    5-77.
    0)
    .


    Grade 3-5 non-hematological toxicity is 35.


    Among patients aged 65-69, 70-74, 75-79, and 80 years old, the 5-year OS rate was 82.


    In the multivariate model (n = 286), hypoalbuminemia (OR, 4.


              Factors related to unplanned hospitalization

              Factors related to unplanned hospitalization Factors related to unplanned hospitalization

    In the multivariate model (n = 286), hypoalbuminemia (OR, 2.
    83; 95% CI, 1.
    43-5.
    58; p = 0.
    003), high comorbidity score (OR, 3.
    93, 95% CI, 1.
    82-8.
    49) ;p = 0.
    001), EPOCH with or without rituximab treatment regimen (OR, 5.
    45; 95%CI, 1.
    45-20.
    5; P = 0.
    012) is associated with a high rate of unplanned hospitalization in the first 6 months after starting treatment
    .

    In the multivariate model (n = 286), hypoalbuminemia (OR, 2.
    83; 95% CI, 1.
    43-5.
    58; p = 0.
    003), high comorbidity score (OR, 3.
    93, 95% CI, 1.
    82-8.
    49) ;p = 0.
    001), EPOCH with or without rituximab treatment regimen (OR, 5.
    45; 95%CI, 1.
    45-20.
    5; P = 0.
    012) is associated with a high rate of unplanned hospitalization in the first 6 months after starting treatment
    .


    In summary, most of the elderly aggressive non-Hodgkin's lymphoma (NHL) treatment survived for more than 5 years, and nearly half of the patients experienced toxicity and unplanned hospitalization
    .


    Therefore, it is necessary to strengthen clinical intervention for these patients
    .

    In summary, most of the elderly aggressive non-Hodgkin's lymphoma (NHL) treatment survived for more than 5 years, and nearly half of the patients experienced toxicity and unplanned hospitalization
    .
    Therefore, it is necessary to strengthen clinical intervention for these patients
    .
    Most elderly patients with aggressive non-Hodgkin's lymphoma (NHL) survive for more than 5 years, and nearly half of the patients experience toxicity and unplanned hospitalization
    .
    Therefore, it is necessary to strengthen clinical intervention for these patients
    .
    Most elderly patients with aggressive non-Hodgkin's lymphoma (NHL) survive for more than 5 years, and nearly half of the patients experience toxicity and unplanned hospitalization
    .
    Therefore, it is necessary to strengthen clinical intervention for these patients
    .

    Original source:

    Original source:

    Johnson PC, Yi A, Horick N,et al.
    Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
    Oncologist.
    2021 Jul 29.
    doi: 10.
    1002/onco.
    13915.
    Epub ahead of print .
    PMID: 34327767.

    Johnson PC, Yi A, Horick N,et al.
    Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
    Oncologist.
    2021 Jul 29.
    doi: 10.
    1002/onco.
    13915.
    Epub ahead of print .
    PMID: 34327767.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.